Collagen (also known as collagen) is the main component of the extracellular matrix (ECM) and is also the most abundant and widely distributed functional protein in mammals. Collagen accounts for 30-40% of the total protein in the human body, of which 70% is in the skin. It plays a variety of important biological functions, such as maintaining the elasticity of skin and muscles, enhancing the binding of calcium and bone cells, connecting bones and muscles, and maintaining corneal transparency.
Recombinant humanized type III collagen
The collagen currently supplied on the market can be mainly divided into animal-derived collagen and genetically recombinant collagen. Among them, genetically recombinant collagen has the characteristics of no potential animal-derived pathogenic factors, single ingredients, controllable quality, low immunogenicity and good scalability of production scale. It is recognized by consumers, the market is growing rapidly, and is gradually being promoted and applied to fields such as regenerative medicine, and has broad development prospects.
Recombinant humanized type III collagen is prepared by using recombinant DNA technology to genetically manipulate and/or modify the full-length or partial amino acid sequence gene encoding the required human type III collagen protein, and then using plasmids or viral vectors to introduce the target gene into host cells (bacteria, yeast or other eukaryotic cells, etc.), express and translate it into collagen or collagen polypeptides, and then extract and purify it.
Technological empowerment
Yaohai Novagen makes a strong breakthrough with recombinant type III humanized collagen
Breaking through technological innovation and adhering to the concept of empowering technology in the medical beauty industry, Yaohai Novagen relies on its parent company Yaohai Bio's mature and complete synthetic microbial high-throughput screening platform and recombinant protein synthesis expression platform to layout the development and research of medical beauty active raw materials and products. With solid molecular construction capabilities, rich process development experience, mature scale-up production and quality management capabilities, the first batch of recombinant type III collagen with independent intellectual property rights has been completed. Yaohai Novagen's recombinant type III humanized collagen is expressed in the Pichia yeast system. The sequence is a core functional segment with high activity, high hydrophilicity and potential triple helix activity selected from the amino acid sequence of human type III collagen. After high-throughput screening of hundreds of molecules, a molecule with 410 amino acids was finally determined. The maximum expression of this molecule in large-scale production can reach more than 50g/L, and the purity of fermentation expression can reach more than 90%; after purification, the purity is close to 100%, and the lowest endotoxin can be less than 0.005EU/mg; after identification, the molecule has a protein tertiary structure and has high activity in stimulating water ion channel proteins, repairing cell damage, and stimulating the expression of type I collagen.
Humanized sequence design and high-throughput screening technology
Developed highly active patented collagen
Safer
● Rich process development capabilities to achieve high purity and low endotoxin (reasonable purification to achieve over 99% purity, endotoxin <0.005EU/mg)
● 100% homologous to human type III collagen, no exogenous sequence inserted, no immunogenicity, higher safety
More efficient
● Promote water ion channel protein, moisturize and nourish the skin
● Promote the production of type I collagen, anti-wrinkle and firming
● Promote cell proliferation and repair skin
More stable
● Complete strain construction and screening research to ensure strain passage and fermentation stability
● Rich experience in large-scale fermentation and aseptic production process control to ensure more stable raw material activity
● Mature biopharmaceutical production and quality control system, more stable product quality
Relying on the parent company Yaohai Bio's rich experience and capabilities in recombinant protein drug research and development, the collagen launched by Yaohai Novagen has the following characteristics: through scientific sequence design, high-throughput screening and optimization, good water solubility and high activity; high purity through high-density fermentation and multi-stage purification process; highly homologous to human collagen and low immunogenicity; recombinant expression, no risk of animal-borne virus infection, high safety; yeast system, ultra-low endotoxin, low allergenicity; full aseptic process control to always maintain high collagen activity and stable quality.
GMP workshop and standardized laboratory
"Derived from medicine, refined in medical beauty". Yaohai Bio is committed to empowering the medical beauty industry with self-developed technology. It has now opened up the entire industry chain of basic research, industrialization and terminal product transformation of recombinant humanized collagen. In the future, Yaohai Bio will continue to adhere to the strategic positioning of "innovation-driven technology, technology-driven service", continue to deepen and improve in the field of medical beauty by continuously building a diversified microbial synthesis technology platform, promote the application of synthetic biology in the field of medical beauty, and realize the beautiful vision of achieving a healthy life.
